Amgen & Merck & Co.

Amgen: Amgen is a key player in the antibody therapeutics market, benefiting from the projected market growth.

Merck & Co.: Merck & Co. is a key player in the antibody therapeutics market, benefiting from the projected market growth.

Amgen: Competitor with injectable PCSK9 inhibitor Repatha; faces potential market share loss to oral alternative.

Merck & Co.: Developer and manufacturer of Lipfendra; approval boosts its cardiovascular pipeline and revenue prospects.

Amgen: Amgen's Repatha is a competitor to Scribe's STX-1150 in the PCSK9 inhibitor space. The success of Scribe's therapy could impact Amgen's market share in cholesterol management.

Merck & Co.: Merck's Lipfendra, the first FDA-approved PCSK9 pill, competes with Scribe's STX-1150. Scribe's epigenetic approach may differentiate it.

Amgen: Andrew Gengos was Vice President of Strategy and Corporate Development at Amgen for eight years.

Merck & Co.: Merck & Co. acquired Terns Pharmaceuticals, where Andrew Gengos previously worked.

Merck & Co.: Merck & Co. struck a deal to cut prices, committing to sell its diabetes drugs Januvia, Janumet, and Janumet XR at 70% off list prices directly to US consumers and pledging $70 billion in US R&D and manufacturing investments.